Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in therapies for central nervous system disorders and rare diseases, has unveiled encouraging preclinical findings stemming from an in vivo investigation into SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion) within an aggressive non-human primate model of Alzheimer’s disease.
The company has also been granted the privilege of presenting a poster featuring these results at Neuroscience 2023, scheduled for November 11-15, 2023, in Washington, D.C.
In this study, researchers utilized older non-human primates (NHPs) overexpressing tau through bilateral AAV-induced tauopathy. The NHPs in the study received one of three treatments: SLS-005 administered weekly, a single dose of SLS-009, or a control treatment. Notably, those receiving SLS-005 exhibited a remarkable 46% reduction in tau protein levels and an 18% decrease in NfL (neurofilament light chain) protein biomarkers when compared to baseline values in an initial analysis.
NfL, a non-specific biomarker, holds significance in various neurodegenerative conditions, encompassing Alzheimer’s disease, multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS).
Krishna Subramanian, Ph.D., Vice President, Non-Clinical Development and Translational Science at Seelos, stated:
“We believe these data from the SLS-005 cohort are highly encouraging and supports SLS-005 as an active drug that targets key biomarkers, including both a broad-based non-specific CNS biomarker like NfL reduction, and a target-specific biomarker such as tau reduction, within six months. These biomarkers are key emerging targets for reduction to treat Alzheimer’s disease and tauopathies. We are also currently completing the analysis of the SLS-009 cohort where the initial results appear promising and expect to release that full dataset when available at a future scientific meeting.”
Furthermore, ongoing analysis of the SLS-009 cohort is anticipated, with initial results showing promise. Seelos expects to unveil the complete dataset at an upcoming scientific gathering.
In addition to these advancements, the fourth quarter of 2023 is earmarked for the release of top-line data from the SLS-005 registrational Phase II/III trial in ALS, a part of the HEALEY ALS Platform Trial led by Harvard Medical School at Massachusetts General Hospital.
About SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion)
SLS-005, a low molecular weight disaccharide (0.342 kDa), boasts the ability to traverse the blood-brain barrier. It is believed to stabilize proteins and activate autophagy through Transcription Factor EB (TFEB) activation, a crucial player in lysosomal and autophagy gene expression. TFEB activation is an emerging therapeutic target for conditions characterized by pathological accumulation of storage materials. Preclinical studies have demonstrated that SLS-005 can reduce the aggregation of misfolded proteins and mitigate the buildup of pathological material. It is important to note that SLS-005 is currently an investigational treatment and has not received approval from any health authority for medicinal use.
About Seelos Therapeutics
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and advancing novel therapeutics to address unmet medical needs for patients dealing with central nervous system (CNS) disorders and other rare diseases. The company’s extensive portfolio encompasses late-stage clinical assets targeting indications such as Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD), amyotrophic lateral sclerosis (ALS), and spinocerebellar ataxia (SCA), in addition to early-stage programs focused on Huntington’s disease, Alzheimer’s disease, and Parkinson’s disease.
For more information, please visit the Seelos Therapeutics website: https://seelostherapeutics.com.
Original Source: /PRNewswire/ — Seelos Therapeutics, Inc. Press Release